AMENDMENT TO
RULES COMMITTEE PRINT 118–10
OFFERED BY MR. BUCK OF COLORADO

Page 1033, after line 14, add the following new section:

SEC. 18__. MDMA-ASSISTED THERAPY AS TREATMENT FOR PTSD.

(a) Sense of Congress.—It is the sense of Congress that—

(1) 3,4-Methylenedioxy-methamphetamine-assisted therapy (in this section referred to as “MDMA-AT”) should be recognized as a treatment for post-traumatic stress disorder (in this section referred to as “PTSD”);

(2) MDMA-AT has shown great scientific promise for treating complex, chronic PTSD, as evidenced by MDMA-AT being designated as a breakthrough therapy under section 506 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356) in 2017 for its use in conjunction with talk therapy to treat PTSD;

(3) the potential of MDMA-AT was confirmed in 2021, when the world’s first phase 3 randomized,
double-blind, placebo-controlled trial found that after 3 MDMA-AT sessions, 67 percent of participants no longer qualified for a PTSD diagnosis, and 88 percent experienced a clinically significant reduction in symptoms;

(4) additional phase 3 clinical trial results further confirmed these findings, and full approval of MDMA-AT under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is now expected in 2024;

(5) thanks to significant private funding, the Nation’s leading academic institutions (including Johns Hopkins University, Yale University, Harvard University, and Stanford University) and governmental institutions (including the Department of Veterans Affairs, the National Institutes of Health, and the Food and Drug Administration) have researched MDMA-AT’s potential for treating PTSD for the past 2 decades; and

(6) MDMA-AT is a worthwhile investment in the mental health of the Nation’s veterans.

(b) PLAN OF ACTION.—Following approval of the use of MDMA-AT as a treatment for PTSD under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the Secretary of Veterans Affairs shall establish a plan
of action to introduce MDMA-AT as a viable treatment for PTSD.